2.0 mg OPT-302 + 0.5 mg ranibizumab
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Neovascular Age-related Macular Degeneration
Conditions
Neovascular Age-related Macular Degeneration
Trial Timeline
Mar 12, 2021 → Mar 31, 2025
NCT ID
NCT04757610About 2.0 mg OPT-302 + 0.5 mg ranibizumab
2.0 mg OPT-302 + 0.5 mg ranibizumab is a phase 3 stage product being developed by Opthea for Neovascular Age-related Macular Degeneration. The current trial status is terminated. This product is registered under clinical trial identifier NCT04757610. Target conditions include Neovascular Age-related Macular Degeneration.
What happened to similar drugs?
18 of 20 similar drugs in Neovascular Age-related Macular Degeneration were approved
Approved (18) Terminated (3) Active (2)
Hype Score Breakdown
Clinical
17
Activity
0
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04757610 | Phase 3 | Terminated |
Competing Products
20 competing products in Neovascular Age-related Macular Degeneration
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CLS-AX + Anti-VEGF | Clearside Biomedical | Phase 1/2 | 22 |
| CLS-AX + Aflibercept | Clearside Biomedical | Phase 2 | 25 |
| Eylea + ALT-L9 | Alteogen | Phase 1 | 29 |
| UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL) | Unity Biotechnology | Phase 2 | 25 |
| DS-7080a + Ranibizumab | Daiichi Sankyo | Phase 1 | 29 |
| Avacincaptad Pegol | Astellas Pharma | Phase 1 | 29 |
| Avacincaptad Pegol + Avastin + Lucentis + Eylea | Astellas Pharma | Phase 2 | 27 |
| Avacincaptad Pegol + Lucentis | Astellas Pharma | Phase 2 | 35 |
| KHK4951 + Aflibercept Injection | Kyowa Kirin | Phase 2 | 39 |
| Surabgene Lomparvovec (ABBV-RGX-314) + Ranibizumab Control | AbbVie | Phase 3 | 47 |
| Ranibizumab + Local Steroid + Topical Steroid | AbbVie | Phase 2 | 39 |
| Lucentis | Novartis | Pre-clinical | 26 |
| ranibizumab | Novartis | Phase 3 | 40 |
| Brolucizumab | Novartis | Pre-clinical | 18 |
| ranibizumab | Novartis | Approved | 43 |
| brolucizumab + ranibizumab + aflibercept | Novartis | Pre-clinical | 26 |
| Beovu | Novartis | Pre-clinical | 26 |
| Ranibizumab | Novartis | Phase 3 | 40 |
| Ranibizumab | Novartis | Approved | 43 |
| Intraviteal Ranibizumab 0.5mg | Novartis | Approved | 43 |